Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.

Goebel G, Berger R, Strasak AM, Egle D, Müller-Holzner E, Schmidt S, Rainer J, Presul E, Parson W, Lang S, Jones A, Widschwendter M, Fiegl H.

Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.

2.

Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.

Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B.

Cancer. 2005 Apr 15;103(8):1631-43.

3.

Dicer, Drosha, and outcomes in patients with ovarian cancer.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK.

N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

4.

Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.

Sun F, Ding W, He JH, Wang XJ, Ma ZB, Li YF.

BMC Cancer. 2015 Oct 20;15:746. doi: 10.1186/s12885-015-1723-x.

5.

Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.

Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R.

Clin Cancer Res. 2002 Jul;8(7):2253-9.

6.

Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.

Carney ME, Maxwell GL, Lancaster JM, Gumbs C, Marks J, Berchuck A, Futreal PA.

J Soc Gynecol Investig. 1998 Sep-Oct;5(5):281-5.

PMID:
9773405
7.

Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.

Abdel-Fatah TM, Russell R, Albarakati N, Maloney DJ, Dorjsuren D, Rueda OM, Moseley P, Mohan V, Sun H, Abbotts R, Mukherjee A, Agarwal D, Illuzzi JL, Jadhav A, Simeonov A, Ball G, Chan S, Caldas C, Ellis IO, Wilson DM 3rd, Madhusudan S.

Mol Oncol. 2014 Oct;8(7):1326-38. doi: 10.1016/j.molonc.2014.04.009. Epub 2014 May 13.

8.

High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.

Xu C, Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, Okumura Y, Yamaguchi L, Fujiki Y, Iwase H.

Breast Cancer. 2014 Jul;21(4):482-90. doi: 10.1007/s12282-012-0403-9. Epub 2012 Sep 12.

PMID:
22968628
9.

PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer.

Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M.

J Transl Med. 2012 Feb 27;10:31. doi: 10.1186/1479-5876-10-31.

10.

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.

Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J.

BMC Cancer. 2006 Sep 29;6:230.

11.

Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.

Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R.

BMC Cancer. 2010 Dec 3;10:666. doi: 10.1186/1471-2407-10-666.

13.

The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.

Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J.

Exp Cell Res. 2005 May 15;306(1):128-41.

PMID:
15878339
14.

Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas.

Bièche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M, Lidereau R.

Br J Cancer. 2003 Mar 24;88(6):863-70.

15.

Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers.

Révillion F, Charlier M, Lhotellier V, Hornez L, Giard S, Baranzelli MC, Djiane J, Peyrat JP.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2088-94.

16.

SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.

Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B.

Hum Pathol. 2012 May;43(5):669-74. doi: 10.1016/j.humpath.2011.06.003. Epub 2011 Aug 19.

PMID:
21855113
17.

Rhomboid domain containing 2 (RHBDD2): a novel cancer-related gene over-expressed in breast cancer.

Abba MC, Lacunza E, Nunez MI, Colussi A, Isla-Larrain M, Segal-Eiras A, Croce MV, Aldaz CM.

Biochim Biophys Acta. 2009 Oct;1792(10):988-97. doi: 10.1016/j.bbadis.2009.07.006. Epub 2009 Jul 17.

18.

Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis.

Yousef GM, Borgoño CA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, Diamandis EP.

Br J Cancer. 2002 Nov 18;87(11):1287-93.

19.

Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.

Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Müller-Holzner E, Jones A, Widschwendter M.

Cancer Sci. 2010 Apr;101(4):1059-66. doi: 10.1111/j.1349-7006.2010.01491.x. Epub 2010 Jan 12.

20.

Transcriptional and post-translational regulation of mouse cation transport regulator homolog 1.

Oh-Hashi K, Nomura Y, Shimada K, Koga H, Hirata Y, Kiuchi K.

Mol Cell Biochem. 2013 Aug;380(1-2):97-106. doi: 10.1007/s11010-013-1663-1. Epub 2013 Apr 25.

PMID:
23615711

Supplemental Content

Support Center